Role of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer
- Authors:
- Meng Wang
- Jing Zhao
- Yan-Jun Su
- Xiao-Liang Zhao
- Chang-Li Wang
View Affiliations
Affiliations: Department of Lung Cancer, Cancer Institute and Hospital, Tianjin Medical University, Key Laboratory of Cancer Prevention and Therapy Tianjin, Tianjin 300060, P.R. China, Department of Breast Cancer, Cancer Institute and Hospital, Tianjin Medical University, Tianjin 300060, P.R. China
- Published online on: September 3, 2012 https://doi.org/10.3892/ol.2012.892
-
Pages:
1349-1353
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Adjuvant chemotherapy is used as an alternative treatment for non-small cell lung cancer (NSCLC); however, the efficiency of post-pneumonectomy adjuvant chemotherapy in NSCLC has not been clarified. In the present study, patients who benefited from adjuvant chemotherapy with TP/NP/GP were identified. A total of 217 patients who underwent pneumonectomy were identified in this study. Of these, 87 underwent pneumonectomy combined with adjuvant chemotherapy (TP/NP/GP regimen) and 130 underwent pneumonectomy only in the initial management. The primary endpoint of the present study was overall survival. Actuarial survival analysis was conducted using the Kaplan-Meier method. Postoperative adjuvant chemotherapy significantly improved the survival rate of patients who underwent left pneumonectomy and in patients with a preoperative forced expiratory volume in 1 sec (FEV1) greater than or equal to 2 l. Age had no effect on the survival rate of patients with or without postoperative adjuvant therapy. Post-pneumonectomy adjuvant chemotherapy is an efficient therapy in NSCLC for patients with preoperative FEV1 greater than or equal to 2 l or who received left pneumonectomy.
View References
|
1.
|
A NiiranenS Niitamo-KorhonenM KouriA
AssendelftK MattsonS PyrhönenAdjuvant chemotherapy after radical
surgery for non-small-cell lung cancer: a randomized studyJ Clin
Oncol101927193219921333518
|
|
2.
|
H WadaS HitomiT TeramatsuAdjuvant
chemotherapy after complete resection in non-small-cell lung
cancer. West Japan Study Group for Lung Cancer SurgeryJ Clin
Oncol14104810541996
|
|
3.
|
H KatoM TsuboiM OhtaE HataN TsubotaN
HamajimaA randomized phase III trial of adjuvant chemotherapy with
UFT for completely resected pathological stage I (T1N0M0, T2N0M0)
adenocarcinoma of the lungProc Am Soc Clin Oncol22abstract
2498200315598942
|
|
4.
|
R ArriagadaB BergmanA DunantT Le
ChevalierJP PignonJ VansteenkisteInternational Adjuvant Lung Cancer
Trial Collaborative GroupCisplatin-based adjuvant chemotherapy in
patients with completely resected non-small-cell lung cancerN Engl
J Med350351360200410.1056/NEJMoa03164414736927
|
|
5.
|
JR RobertsC EustisR DevoreD CarboneH ChoyD
JohnsonInduction chemotherapy increases perioperative complications
in patients undergoing resection for non-small cell lung cancerAnn
Thorac Surg72885888200110.1016/S0003-4975(01)02836-3
|
|
6.
|
N NovoaG VarelaMF JimenezMorbidity after
surgery for non-small cell lung carcinoma is not related to
neoadjuvant chemotherapyEur J Cardiothorac
Surg20700704200110.1016/S1010-7940(01)00876-4
|
|
7.
|
CF MountainValue of the new TNM staging
system for lung cancerChest961
Suppl47S49S198910.1378/chest.96.1_Supplement.47S2544360
|
|
8.
|
CF MountainRevisions in the International
System for Staging Lung
CancerChest11117101717199710.1378/chest.111.6.17109187198
|
|
9.
|
J WangJ OlakRE UltmannMK
FergusonAssessment of pulmonary complications after lung
resectionAnn Thorac
Surg6714441447199910.1016/S0003-4975(99)00255-610355428
|
|
10.
|
British Thoracic SocietySociety of
Cardiothoracic Surgeons of Great Britain and Ireland Working
PartyBTS guidelines: guidelines on the selection of patients with
lung cancer for
surgeryThorax5689108200110.1136/thorax.56.2.8911209097
|
|
11.
|
AM NugentIC SteeleAM CarragherK McManusJA
McGuiganJR GibbonsEffect of thoracotomy and lung resection on
exercise capacity in patients with lung
cancerThorax54334338199910.1136/thx.54.4.33410092695
|
|
12.
|
KR LarsenUG SvendsenN MilmanJ BrenøeB
PetersenCardiopulmonary function at rest and during exercise after
resection for bronchial carcinomaAnn Thorac
Surg64960964199710.1016/S0003-4975(97)00635-89354509
|
|
13.
|
DE StoverRJ KanerAdverse effects of
treatment: pulmonary toxicityCancer Principles & Practice of
OncologyVT De VitaS HellmanAA Rosenberg7th editionLippincott
Williams & WillkinsPhiladelphia253925452004
|
|
14.
|
L ChapR ShpinerM LevineL NortonM LillJ
GlaspyPulmonary toxicity of high-dose chemotherapy for breast
cancer: a non-invasive approach to diagnosis and treatmentBone
Marrow Transplant2010631067199710.1038/sj.bmt.17010289466279
|
|
15.
|
T WintonR LivingstonD JohnsonJ RigasM
JohnstonC ButtsNational Cancer Institute of Canada Clinical Trials
GroupNational Cancer Institute of the United States Intergroup
JBR.10 Trial InvestigatorsVinorelbine plus cisplatin vs.
observation in resected non-small-cell lung cancerN Engl J
Med35225892597200510.1056/NEJMoa043623
|
|
16.
|
J MartinRJ GinsbergA AbolhodaMS BainsRJ
DowneyRJ KorstMorbidity and mortality after neoadjuvant therapy for
lung cancer: the risks of right pneumonectomyAnn Thorac
Surg7211491154200110.1016/S0003-4975(01)02995-211603428
|
|
17.
|
C DoddoliF BarlesiD TrousseS RobitailS
YenaP AstoulOne hundred consecutive pneumonectomies after induction
therapy for non-small cell lung cancer: an uncertain balance
between risks and benefitsJ Thorac Cardiovasc
Surg130416425200510.1016/j.jtcvs.2004.11.022
|
